Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 (daunorubicin and cytarabine)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal encapsulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio. This formulation is designed to optimize the synergistic ratio of the two drugs while protecting them from degradation and enhancing delivery to the bone marrow. It is primarily used for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The mechanism involves cytarabine's inhibition of DNA polymerase and daunorubicin's intercalation into DNA and inhibition of topoisomerase II. The liposomal delivery system allows for prolonged exposure and preferential uptake by leukemia cells in the bone marrow.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposomedaunorubicin and cytarabine liposome
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)Pol III (Dna-directed RNA polymerase III)
Beyond the preview
Go deeper on CPX-351 (daunorubicin and cytarabine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 (daunorubicin and cytarabine).